Similarly, SGLT-2 inhibitors, may prevent release of pro-inflammatory cytokines and increase the production of angiotensin 17, thus protecting against the development of ARDS [77]; however, at the same time, they have been reported to increase the risk of AKI and hemodynamic instability during acute systemic infection [73]. Here, SLC5A2 is linked to acute kidney injury.